Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. - Wikidata - wikimedia - TriplyDB

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

http://www.wikidata.org/entity/Q34612644

about

Thrombopoietin mimetics for patients with myelodysplastic syndromes Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy MDS prognostic scoring systems – past, present, and future Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Clinical and genetic predictors of prognosis in myelodysplastic syndromes.A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.Current therapy of myelodysplastic syndromes There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Myelodysplastic syndromes: diagnosis, prognosis, and treatment.The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores Revised international prognostic scoring system for myelodysplastic syndromes.A simplified score to quantify comorbidity in COPD Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota.Managing myelodysplastic syndromes in very old patients: a teaching case report.Comorbidities predict worse prognosis in patients with primary myelofibrosis Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Deriving comorbidities from medical records using natural language processing.Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.Why methylation is not a marker predictive of response to hypomethylating agents.Myelodysplastic Syndromes and Iron Chelation Therapy Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.Acute myeloid leukemia and myelodysplastic syndromes in older adults.The myelodysplastic syndromes: the era of understanding.Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.A retrospective study evaluating the impact of infectious complications during azacitidine treatment.Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.Improving Prognostic Modeling in Myelodysplastic Syndromes.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant.

P2860

Q24198060-16EC66B4-E605-4CAE-936F-B23B6A71B7BE Q26796240-1FEAF14B-179C-49D5-A2AF-FEE00C019914 Q27010653-6A92EDE8-3DA7-46AE-B9BA-776BFF5A7060 Q28082460-5FD4493B-7818-48E3-8CAA-32CCDE1732D8 Q30235355-9F4C1FA7-1100-42CC-AB62-38EFA6059064 Q33695906-C457F499-058A-4F0E-84EB-7B12F5F8BB1C Q33877952-8C933F7E-8ABB-409A-8744-78EE3BE261D3 Q33945004-5BCFFBFB-ADB0-4A13-A268-9769305C67CF Q34013796-6644467B-706E-4EDF-8E68-D3262BECA54A Q34049017-BB7AD5BE-59F6-415B-BE40-6AC5CBE7DB67 Q34273735-559601CA-7155-422F-83CC-74E0AE555550 Q34389508-76CC46E2-1256-4FED-BE3F-A0EDE306B82C Q34520113-3A5E56C3-2BA3-4E11-9123-4456C94A0F21 Q34639717-78F3258E-8DBF-45DF-83CF-018901FC5A71 Q34712570-578EB003-3489-40B9-B468-24A182AE208B Q35265820-0FBF2074-E9AA-447A-B8AA-822C0BDA1655 Q36499044-BEAA8259-D20A-4812-B100-DAA0F13BF020 Q36772626-BF8B83B3-8ACC-4C92-8E1A-96898C157C01 Q36817560-59D33E19-211C-49FE-BE70-1EED5F72E94A Q36879957-6211E089-2683-46D6-85D1-0381FAEFDEBA Q37263146-BFDAD340-1049-49C6-84B9-3F0840CDC065 Q37389458-EF0B9A37-1DAB-4325-BCDC-FF7AECC1AD47 Q37441528-C37ECCDC-AD78-411D-B18D-D66A28D7AD3D Q37618945-89173A41-479A-4E52-9994-5F619D40F03E Q37676259-6554CD74-79BB-48D1-9D75-07A87ABE1059 Q37677229-B5FEC9C5-F914-4037-BC2C-400B721D4061 Q37889846-1902DF59-6125-4421-B093-60621F79A78E Q38037118-A8B8DB4E-AD85-4468-8CF3-8E4FEC1C4CD2 Q38181996-DC3BFAB1-CB82-4DB6-AF89-73C953667244 Q38225750-974E1F42-14CE-41C6-8870-721776EFBA30 Q38234863-C79AE381-F7C0-4559-A10D-B87E070FA5D6 Q38245878-BAAF265F-A6BA-4BE1-BF7B-2C92F192036E Q38394646-D243BB8C-DAA4-4CFD-8AFF-273E9199FE2D Q38651372-7E659C59-5FF1-4EE8-BF66-42624B088B62 Q38678113-B11911E8-9232-47FD-A16B-A366D91ACB0D Q38803021-C2BCE0E0-28D1-400E-8DF4-36D3D46E9C69 Q38880077-B0DAEB32-1A55-4113-8E4D-3BA57C67CCC5 Q38922020-CE3CD703-706E-4886-9AFA-19A3D29C4E25 Q39413114-385622D6-84AD-4D20-B588-9F6C62DC5772 Q39805438-B242A9B8-C4B7-40FA-8CCC-5483D943662A

P2860

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

http://www.wikidata.org/entity/Q34612644

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Risk stratification based on b ...... with myelodysplastic syndrome.

@ast

Risk stratification based on b ...... with myelodysplastic syndrome.

@en

Risk stratification based on b ...... with myelodysplastic syndrome.

@nl

type

label

Risk stratification based on b ...... with myelodysplastic syndrome.

@ast

Risk stratification based on b ...... with myelodysplastic syndrome.

@en

Risk stratification based on b ...... with myelodysplastic syndrome.

@nl

prefLabel

Risk stratification based on b ...... with myelodysplastic syndrome.

@ast

Risk stratification based on b ...... with myelodysplastic syndrome.

@en

Risk stratification based on b ...... with myelodysplastic syndrome.

@nl

P1433

Q34612644-32C8B16F-1246-4D7D-AEED-FAF33A8CB8B7

P1476

Q34612644-2A7BAC63-C680-4ED8-B354-8B498226E3A9

P2093

Q34612644-13EA3E3C-37A9-4695-98BF-BA12DB64F2F0

Q34612644-162C64A9-ED03-4833-84B2-28AD1B28CD3F

Q34612644-849B3F42-F219-458F-8B71-DDB2AA08DD98

Q34612644-8C33EF19-BBDB-43E4-95B7-E4D15D37C949

Q34612644-8CE12EF6-26D5-4736-9DE8-C8BF4EC25420

Q34612644-91BD91B4-9A90-4FD7-9022-1D64CF9C913C

Q34612644-962E7746-1670-4C79-A1EE-B7E6D204FE77

Q34612644-A5D68A2E-F61D-41A6-8077-9E8BFD35277B

Q34612644-E04FB74F-070C-4B84-A9DA-2FAA4CC0B578

Q34612644-E429CAC0-6710-4C74-B535-F435998F97A7

P2860

Q34612644-14A2385B-A1B1-4603-8B7C-1A7B0FB2D931

Q34612644-28AEF16D-8A66-4DD1-8259-E14FB3EE4CC5

Q34612644-33A3F5B6-663C-4B59-B719-82F6A3CBE6D5

Q34612644-473AB62A-14F2-46C6-B8F3-70D1CA7130F3

Q34612644-479E3903-9602-4B97-8D40-43AF41B027CF

Q34612644-5C4372DB-0EFA-49F4-B376-26EAE0A99978

Q34612644-6EE3E1BB-C47E-407F-AABA-C6D2B74B2ADC

Q34612644-7783CAAB-7658-41E6-90CA-5FC0EC927E72

Q34612644-78781F51-52FC-4EC3-AAC0-408E82D71FD4

Q34612644-8002B9A7-B64C-4D27-B43B-12B3993446E7

P304

Q34612644-8C8D0F23-FB55-4824-95B1-DDA92FA4FB41

P31

Q34612644-52ECFBE1-425A-447E-B0A5-0A3AEDE53DBA

P356

Q34612644-F9B5E8F6-9494-4CCA-B73D-E1B2956FC8EE

P433

Q34612644-E9D9C1C1-2C16-4AA9-8722-6AF40CD6E800

P478

Q34612644-4084C10A-CFA9-4CD1-A819-E130BA4A5508

P50

Q34612644-8CC8610F-4123-4CBC-8E93-3A13290795FB

P577

Q34612644-682B86B6-FF6F-4E0E-99E0-B0D5BEBDD0AF

P5875

Q34612644-4354A79E-6E01-4CBB-8DC5-8F851C0DA475

P698

Q34612644-63DF7F19-F1A1-47DA-A1DB-BB73EB10B520

P921

Q34612644-7FF404C5-9D82-47D8-B407-979D0A0EB2B4

P932

Q34612644-067055D7-71C1-4987-851A-1A2B1A5E18FE

P356

HAEMATOL.2010.033506

P1433

P1476

Risk stratification based on b ...... with myelodysplastic syndrome.

@en

P2093

Andrea Kuendgen

http://www.w3.org/2001/XMLSchema#string

Corinna Strupp

http://www.w3.org/2001/XMLSchema#string

Cristiana Pascutto

http://www.w3.org/2001/XMLSchema#string

Erica Travaglino

http://www.w3.org/2001/XMLSchema#string

Esther Zipperer

http://www.w3.org/2001/XMLSchema#string

Ilaria Ambaglio

http://www.w3.org/2001/XMLSchema#string

Luca Malcovati

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

Mario Lazzarino

http://www.w3.org/2001/XMLSchema#string

Matteo G Della Porta

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

The World Health Organization (WHO) classification of the myeloid neoplasms

Proposals for the classification of the myelodysplastic syndromes

International scoring system for evaluating prognosis in myelodysplastic syndromes

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

P304

441-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2010.033506

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49661501

http://www.w3.org/2001/XMLSchema#string

P698

21134982

http://www.w3.org/2001/XMLSchema#string

P921

P932

3046276

http://www.w3.org/2001/XMLSchema#string